Retinal toxicity related to hydroxychloroquine in patients with systemic lupus erythematosus and rheumatoid arthritis
- PMID: 28852896
- DOI: 10.1007/s10633-017-9607-9
Retinal toxicity related to hydroxychloroquine in patients with systemic lupus erythematosus and rheumatoid arthritis
Abstract
Purpose: To compare the retinal toxicity due to hydroxychloroquine (HCQ) use in patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) using multifocal electroretinography (mfERG), fundus autofluorescence (FAF) and optical coherence tomography (OCT).
Methods: Patients who were using HCQ due to SLE and RA, and healthy subjects evaluated in this study. Central foveal thickness (CFT), inner-outer segment (IS-OS) junction irregularity, retinal nerve fiber layer thickness, mfERG and FAF measurements were performed to evaluate retinal toxicity.
Results: Study included 35 eyes of 35 SLE patients, 40 eyes of 40 RA patients and 20 eyes of 20 healthy subjects. In SLE group, retinal abnormality was found in three eyes with mfERG, in one eye with FAF and in four eyes with OCT. In RA group, retinal abnormality was found in 10 eyes with mfERG, in five eyes with FAF and in nine eyes with OCT. A statistically significant difference was found with respect to mfERG between "eyes with abnormal responses and without abnormal responses" and "eyes with abnormal responses and controls" (p < 0.05). A statistically significant difference was found with respect to CFT between "eyes with IS-OS junction irregularities and without IS-OS junction irregularities" and "eyes with/without IS-OS junction irregularities and controls" (p < 0.05).
Conclusions: The use of HCQ seems to cause retinal toxicity more often in RA patients compared to SLE patients. For the early detection of retinal changes, OCT and mfERG can be used as screening tools due to their higher sensitivity rates compared to other tests.
Keywords: Fundus autofluorescence; Hydroxychloroquine toxicity; Multifocal electroretinography; Optical coherence tomography; Rheumatoid arthritis; Systemic lupus erythematosus.
Comment in
-
Response to risk of hydroxychloroquine retinopathy is not related to systemic lupus erythematosus or rheumatoid arthritis.Doc Ophthalmol. 2018 Feb;136(1):95-96. doi: 10.1007/s10633-018-9624-3. Epub 2018 Jan 30. Doc Ophthalmol. 2018. PMID: 29383473 No abstract available.
-
Retinopathy from hydroxychloroquine is not related to lupus or rheumatoid arthritis.Doc Ophthalmol. 2018 Feb;136(1):93-94. doi: 10.1007/s10633-018-9623-4. Epub 2018 Jan 30. Doc Ophthalmol. 2018. PMID: 29383474 No abstract available.
Similar articles
-
Multifocal electroretinographic evaluation of long-term hydroxychloroquine users.Arch Ophthalmol. 2004 Jul;122(7):973-81. doi: 10.1001/archopht.122.7.973. Arch Ophthalmol. 2004. PMID: 15249360
-
Subjective and objective screening tests for hydroxychloroquine toxicity.Ophthalmology. 2015 Feb;122(2):356-66. doi: 10.1016/j.ophtha.2014.07.056. Epub 2014 Oct 14. Ophthalmology. 2015. PMID: 25444344 Free PMC article.
-
Detection of early hydroxychloroquine retinal toxicity enhanced by ring ratio analysis of multifocal electroretinography.Am J Ophthalmol. 2007 May;143(5):801-809. doi: 10.1016/j.ajo.2006.12.042. Epub 2007 Mar 6. Am J Ophthalmol. 2007. PMID: 17336914
-
Hydroxychloroquine-related retinal toxicity.Rheumatology (Oxford). 2016 Jun;55(6):957-67. doi: 10.1093/rheumatology/kev357. Epub 2015 Oct 1. Rheumatology (Oxford). 2016. PMID: 26428520 Review.
-
Ocular toxicity due to chloroquine and hydroxychloroquine: electrophysiological and visual function correlates.Doc Ophthalmol. 2005 Jan;110(1):111-20. doi: 10.1007/s10633-005-7349-6. Doc Ophthalmol. 2005. PMID: 16249962 Review.
Cited by
-
Evaluation of optical coherence tomography angiography parameters in patients treated with Hydroxychloroquine.BMC Ophthalmol. 2021 May 11;21(1):209. doi: 10.1186/s12886-021-01977-5. BMC Ophthalmol. 2021. PMID: 33975575 Free PMC article.
-
Response to risk of hydroxychloroquine retinopathy is not related to systemic lupus erythematosus or rheumatoid arthritis.Doc Ophthalmol. 2018 Feb;136(1):95-96. doi: 10.1007/s10633-018-9624-3. Epub 2018 Jan 30. Doc Ophthalmol. 2018. PMID: 29383473 No abstract available.
-
Cone Density Distribution and Related Factors in Patients Receiving Hydroxychloroquine Treatment.Invest Ophthalmol Vis Sci. 2023 Sep 1;64(12):29. doi: 10.1167/iovs.64.12.29. Invest Ophthalmol Vis Sci. 2023. PMID: 37713205 Free PMC article.
-
Retinopathy from hydroxychloroquine is not related to lupus or rheumatoid arthritis.Doc Ophthalmol. 2018 Feb;136(1):93-94. doi: 10.1007/s10633-018-9623-4. Epub 2018 Jan 30. Doc Ophthalmol. 2018. PMID: 29383474 No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical